glp-1 wonder drug GLP-1s: Miracle or missed opportunity? GLP-1s have been called 'wonder

As I warned shortly after the IRA was passed, the IRA will ultimately lead to fewer biosimilar launches, because the prospects of future negotiation could reduce biosimilar development

Their benefits, such as improved glycaemic control, support for weight management, and potential cardiovascular protection, are well documented in clinical studies

This study aimed to summarize these indicators through a meta-analysis

What's more, the health benefits seen when taking these drugs, such as reductions in blood pressure, blood glucose, and lipids, also disappear

Due to supply and funding constraints, most UK patients cannot access semaglutide 2.4 mg, even in specialist services

Here are the public health implications for these new research findings